6 Einträge gefunden

1. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization:Insights From VOYAGER PAD

   1. Hess, Connie N
   2. Baumgartner, Iris
   3. Anand, Sonia S
   4. Nehler, Mark R
   5. Patel, Manesh R
   6. Debus, E Sebastian
   7. Szarek, Michael

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial:The XATOA Registry

   1. Fox, Keith A A
   2. Aboyans, Victor
   3. Debus, E Sebastian
   4. Zeymer, Uwe
   5. Cowie, Martin R
   6. Patel, Manesh
   7. Welsh, Robert C

   2022 - Forschungsinformationssystem des UKE
3. Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization

   1. Hess, Connie N
   2. Szarek, Michael
   3. Anand, Sonia S
   4. Bauersachs, Rupert M
   5. Patel, Manesh R
   6. Debus, E Sebastian
   7. Nehler, Mark R

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial:Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone

   1. Berkowitz, Scott D
   2. Bauersachs, Rupert M
   3. Szarek, Michael
   4. Nehler, Mark R
   5. Debus, E Sebastian
   6. Patel, Manesh R
   7. Anand, Sonia S

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery:A post hoc analysis of a "CASPAR like" outcome from VOYAGER PAD

   1. Bonaca, Marc P
   2. Szarek, Michael
   3. Debus, E Sebastian
   4. Nehler, Mark R
   5. Patel, Manesh R
   6. Anand, Sonia S
   7. Muehlhofer, Eva

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
6. Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both

   1. Fox, Keith A A
   2. Anand, Sonia S
   3. Aboyans, Victor
   4. Cowie, Martin R
   5. Debus, E Sebastian
   6. Zeymer, Uwe
   7. Monje, Danja

   2020 - Forschungsinformationssystem des UKE